Zacks Investment Research cut shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

A number of other equities research analysts also recently issued reports on OXFD. BTIG Research reissued a buy rating on shares of Oxford Immunotec Global PLC in a research report on Thursday, May 4th. ValuEngine raised shares of Oxford Immunotec Global PLC from a sell rating to a hold rating in a research report on Friday, June 2nd. Piper Jaffray Companies reissued a buy rating and set a $26.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Finally, Cowen and Company reissued a buy rating and set a $22.00 price objective on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Oxford Immunotec Global PLC has a consensus rating of Hold and a consensus price target of $21.00.

Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) opened at 18.02 on Friday. The firm’s 50 day moving average price is $16.18 and its 200 day moving average price is $14.93. Oxford Immunotec Global PLC has a 52-week low of $8.88 and a 52-week high of $19.51. The stock’s market cap is $415.83 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last issued its quarterly earnings data on Tuesday, August 1st. The company reported ($0.32) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.32). Oxford Immunotec Global PLC had a negative net margin of 34.58% and a negative return on equity of 35.76%. The firm had revenue of $26.10 million during the quarter, compared to the consensus estimate of $25.05 million. During the same quarter in the previous year, the firm posted ($0.29) EPS. The company’s revenue for the quarter was up 35.9% compared to the same quarter last year. On average, analysts expect that Oxford Immunotec Global PLC will post ($1.07) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Oxford Immunotec Global PLC (OXFD) Stock Rating Lowered by Zacks Investment Research” was published by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/08/oxford-immunotec-global-plc-oxfd-stock-rating-lowered-by-zacks-investment-research.html.

In related news, CEO Peter Wrighton-Smith sold 30,000 shares of the company’s stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $16.06, for a total value of $481,800.00. Following the completion of the transaction, the chief executive officer now owns 491,668 shares of the company’s stock, valued at approximately $7,896,188.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $14.40, for a total transaction of $43,200.00. Following the completion of the transaction, the director now directly owns 20,174 shares of the company’s stock, valued at approximately $290,505.60. The disclosure for this sale can be found here. Insiders sold a total of 107,085 shares of company stock valued at $1,710,328 in the last ninety days. 7.58% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors increased its position in shares of Oxford Immunotec Global PLC by 1.9% in the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock valued at $213,000 after buying an additional 254 shares in the last quarter. American International Group Inc. boosted its stake in shares of Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock valued at $212,000 after buying an additional 904 shares during the last quarter. Parkwood LLC boosted its stake in shares of Oxford Immunotec Global PLC by 12.9% in the second quarter. Parkwood LLC now owns 12,799 shares of the company’s stock valued at $215,000 after buying an additional 1,465 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Oxford Immunotec Global PLC by 9.1% in the second quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock valued at $412,000 after buying an additional 2,053 shares during the last quarter. Finally, TFS Capital LLC boosted its stake in shares of Oxford Immunotec Global PLC by 19.8% in the first quarter. TFS Capital LLC now owns 14,125 shares of the company’s stock valued at $219,000 after buying an additional 2,337 shares during the last quarter. 87.03% of the stock is owned by institutional investors.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.